. Respectivement, La baisse reste significative à 1 an de l'arrêt du traitement avec une médiane de leucocytes à 6685/mm 3 (5340 ; 7450) (p=0,022) La baisse des PNN (polynucléaires neutrophiles) et des lymphocytes aux mêmes dates n'était pas significative. Aucun patient n'a eu de neutropénie < 500/mm 3

. Les-douze-patients, analysé à deux temps différents) ayant reçu du rituximab (n=12) ou de l'endoxan (n=2, 16,7%) avant le début de Leva-MMF ont été analysés séparément (patients n°1, pp.13-18

. Mg, an (580 ; 4750) et de 24 (0 ; 1468) l'année après J0. Il n'y a pas de différence significative mais un forte tendance à la diminution (p=0,055), Les corticoïdes ont pu être arrêtés au moins temporairement chez 10 patients (76,9 %) pendant Leva-MMF, p.8

%. De-leva-mmf, Le nombre de rechutes médian l'année avant J0 est de 2,0 rechutes/an (1,0

B. 1. Deschênes, G. Doucet, and A. , Free immunoglobulin light chains: A role in minimal change disease, Bioscience Hypotheses, vol.2, issue.3, pp.135-177, 2009.
DOI : 10.1016/j.bihy.2009.03.001

H. Autorité and D. Santé, Protocole National de Diagnostic et de Soins pour une maladie rare. Syndrome Néphrotique Idiopathique de l'enfant, 2008.

A. Eddy and J. Symons, Nephrotic syndrome in childhood. The Lancet, 23 août, vol.362, issue.9384, pp.629-668, 2003.

R. Lombel, D. Gipson, and E. Hodson, Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO, Pediatric Nephrology, vol.20, issue.Suppl 1, pp.415-441, 2013.
DOI : 10.1007/s00467-012-2310-x

D. Gipson, S. Massengill, L. Yao, S. Nagaraj, W. Smoyer et al., Management of Childhood Onset Nephrotic Syndrome, PEDIATRICS, vol.124, issue.2, pp.747-57, 2009.
DOI : 10.1542/peds.2008-1559

E. Hodson and S. Alexander, Evaluation and management of steroid-sensitive nephrotic syndrome, Current Opinion in Pediatrics, vol.20, issue.2, pp.145-50, 2008.
DOI : 10.1097/MOP.0b013e3282f4307a

E. Schlesinger, H. Sultz, W. Mosher, and J. Feldman, The Nephrotic Syndrome, American Journal of Diseases of Children, vol.116, issue.6, pp.623-655, 1968.
DOI : 10.1001/archpedi.1968.02100020627009

G. Deschênes and A. Leclerc, ??pid??miologie du syndrome n??phrotique de l???enfant, Archives de P??diatrie, vol.17, issue.6, pp.622-625, 2010.
DOI : 10.1016/S0929-693X(10)70028-2

M. Saleem, O. Hare, M. Reiser, J. Coward, R. Inward et al., A Conditionally Immortalized Human Podocyte Cell Line Demonstrating Nephrin and Podocin Expression, JASN. 3 janv, vol.13, issue.3, pp.630-638, 2002.

S. Zhang, . Yu, V. Audard, Q. Fan, A. Pawlak et al., Immunopathogenesis of idiopathic nephrotic syndrome Handbook of Pediatric Nephrology 12. ISKDC. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children, 94?106. 11. Niaudet P561?4. 13. Bonilla-Felix M, 1981.

S. Gulati, A. Sharma, R. Sharma, A. Gupta, K. Kaneko et al., Changing trends of histopathology in childhood nephrotic syndrome Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes, Am J Kidney Dis. oct World J Pediatr. févr, vol.3411, issue.151, pp.21-29, 1999.

J. Davin, The glomerular permeability factors in idiopathic nephrotic syndrome, Pediatric Nephrology, vol.25, issue.85
DOI : 10.1007/s00467-015-3082-x

L. Leventhal, J. Skaro, A. Kanwar, Y. Alvarado, and A. , Resolution of recurrent focal segmental glomerulosclerosis after retransplantation, Pediatr Nephrol N Engl J Med. 26 avr, vol.366, issue.17, pp.1648-1657, 2012.

J. Hoyer, R. Vernier, J. Najarian, L. Raij, R. Simmons et al., RECURRENCE OF IDIOPATHIC NEPHROTIC SYNDROME AFTER RENAL TRANSPLANTATION, The Lancet, vol.300, issue.7773, pp.343-351, 1972.
DOI : 10.1016/S0140-6736(72)91734-5

A. Ali, E. Wilson, J. Moorhead, P. Amlot, A. Abdulla et al., Minimalchange glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation. 15 oct, pp.849-52, 1994.

M. Kemper, G. Wolf, and D. Müller-wiefel, Transmission of Glomerular Permeability Factor from a Mother to Her Child, New England Journal of Medicine, vol.344, issue.5, pp.386-393, 2001.
DOI : 10.1056/NEJM200102013440517

R. Shalhoub, PATHOGENESIS OF LIPOID NEPHROSIS: A DISORDER OF T-CELL FUNCTION, The Lancet, vol.304, issue.7880
DOI : 10.1016/S0140-6736(74)91880-7

M. Kemper, T. Meyer-jark, M. Lilova, and D. Müller-wiefel, Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome, Clinical Nephrology, vol.60, issue.10, pp.242-249, 2003.
DOI : 10.5414/CNP60242

R. Fujinami, X. Sun, J. Howell, J. Jenkin, and J. Burns, Modulation of Immune System Function by Measles Virus Infection: Role of Soluble Factor and Direct Infection, J Virol. 12 janv, vol.72, issue.12, pp.9421-9428, 1998.

K. Andréau, C. Lemaire, V. Souvannavong, and A. Adam, Induction of apoptosis by dexamethasone in the B cell lineage, Immunopharmacology, vol.40, issue.1, pp.67-76, 1998.
DOI : 10.1016/S0162-3109(98)00034-4

A. Allison and E. Eugui, Mycophenolate mofetil and its mechanisms of action, Immunopharmacology, vol.47, issue.2-3, pp.85-118, 2000.
DOI : 10.1016/S0162-3109(00)00188-0

J. Lacki, S. Mackiewicz, P. Leszczynski, and W. Müller, The effect of intravenous cyclophosphamide pulse on peripheral blood lymphocytes in lupus erythematosus patients, Rheumatology International, vol.17, issue.2, pp.55-60, 1997.
DOI : 10.1007/PL00006852

J. Dantal, E. Bigot, W. Bogers, A. Testa, F. Kriaa et al., Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial, N Engl J Med. 6 janv Lancet. 4 oct, vol.330384, issue.19950, pp.7-14, 1994.

K. Lai, C. Wei, L. Tan, P. Tan, G. Chiang et al., Overexpression of Interleukin-13 Induces Minimal-Change-Like Nephropathy in Rats, ):1476?85. 32. Bakker WW, 2007.
DOI : 10.1681/ASN.2006070710

R. Lennon, A. Singh, G. Welsh, R. Coward, S. Satchell et al., Hemopexin Induces Nephrin-Dependent Reorganization of the Actin Cytoskeleton in Podocytes, 1410?5. 33, pp.2140-2149, 2005.
DOI : 10.1681/ASN.2007080940

S. Zhang, M. Kamal, K. Dahan, A. Pawlak, V. Ory et al., c-mip Impairs Podocyte Proximal Signaling and Induces Heavy Proteinuria, ra39. 35. Clement LC, 2010.
DOI : 10.1126/scisignal.2000678

URL : https://hal.archives-ouvertes.fr/inserm-00489747

L. Jiang, I. Dasgupta, J. Hurcombe, H. Colyer, P. Mathieson et al., Levamisole in steroid-sensitive nephrotic syndrome: usefulness in adult patients and laboratory insights into mechanisms of action via direct action on the kidney podocyte Metabolic changes associated with administration of adrenocorticotropin in the nephrotic syndrome, 883?93. 38. Farnsworth EB, pp.60-62, 1950.

. Syndrome-néphrotique-pur, Protocole de traitement proposé par la Société de Néphrologie Pédiatrique):150?6. 40. APN. Alternate-day prednisone is more effective than intermittent prednisone in frequently relapsing nephrotic syndrome. A report ofArbeitsgemeinschaft für Pädiatrische Nephrologie, 229?37. 41. APN. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie, pp.380-383, 1981.

E. Hodson, J. Craig, N. Willis, J. Kist-van-holthe, N. Van-rijswijk et al., Evidence-based management of steroid-sensitive nephrotic syndrome Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle, 1523?30. 43. Teeninga N, pp.149-59, 2005.

N. Yoshikawa, K. Nakanishi, M. Sako, M. Oba, R. Mori et al., A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment Corticosteroids for the initial episode of steroidsensitive nephrotic syndrome Complications of nephrotic syndrome On the biochemical mode of action of levamisole: An update Treatment of nephrotic syndrome with levamisole, 225?32. 46. Hodson EM322?8. 48. Van Wauwe J, pp.29-48, 1980.

M. Skok, R. Grailhe, F. Agenes, and J. Changeux, The role of nicotinic receptors in Blymphocyte development and activation, Life Sci. 30 mai, vol.80, pp.24-252334, 2007.
URL : https://hal.archives-ouvertes.fr/pasteur-00162141

K. Rezvani, Y. Teng, D. Shim, D. Biasi, M. Szewczyk et al., Nicotine regulates multiple synaptic proteins by inhibiting proteasomal activity Genetic defects in acetylcholine signalling promote protein degradation in muscle cells of Caenorhabditis elegans, J Neurosci. 26 sept J Cell Sci. juin, vol.27113, issue.39, pp.10508-10527, 2000.

Y. Kang, H. Jin, G. Zheng, Q. Xie, J. Yin et al., The adjuvant effect of levamisole on killed viral vaccines Anti-helminthic drugs in recurrent apthous stomatitis: A short review, 5543?50. 55, pp.48-4965, 2005.

H. Stevenson, I. Green, J. Hamilton, B. Calabro, and D. Parkinson, Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome, JC. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children, 1991.

S. Priyadarshini, O. Boyer, J. Moulder, L. Grandin, and M. Somers, Efficacy of levamisole in children with frequently relapsing and steroiddependent nephrotic syndrome Short-and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome):575?80. 61. Elmas AT, Tabel Y, Elmas ON. Short-and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome, 371?3. 60, pp.1047-55, 2008.

J. Davin, M. Merkus, L. Fu, and C. Chi, Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? Liver toxicity in a nephrotic patient treated with levamisole Levamisole in steroid-sensitive nephrotic syndrome children with steroid-dependency and/or frequent relapses, 10?4. 63. Bulugahapitiya DT80?4. 65. Niaudet P, Drachman R, Gagnadoux MF, Broyer M. Treatment of idiopathic nephrotic syndrome with levamisole, pp.289637-289678, 1984.

V. Sümegi, I. Haszon, B. Iványi, C. Bereczki, F. Papp et al., Long-term effects of levamisole treatment in childhood nephrotic syndrome Levamisole induced ataxia Side effects of levamisole in children with nephrosis, 1354?60. 67. Dubey AK417?9. 68. Palcoux JB263?4. 69. Barbano G, pp.602-605, 1994.

F. Rongioletti, L. Ghio, F. Ginevri, D. Bleidl, S. Rinaldi et al., Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children, British Journal of Dermatology, vol.36, issue.5, pp.948-51, 1999.
DOI : 10.1046/j.1365-2133.1999.02833.x

A. Allison and E. Eugui, Mechanisms of Action of Mycophenolate Mofetil in Preventing Acute and Chronic Allograft Rejection, Transplantation, vol.80, issue.Supplement, pp.181-90, 2005.
DOI : 10.1097/01.tp.0000186390.10150.66

W. Zhao, V. Elie, V. Baudouin, A. Bensman, J. André et al., Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome, Br J Clin Pharmacol. avr Am J Kidney Dis. déc, vol.6942, issue.46, pp.1114-1134, 2003.

J. Gellermann, U. Querfeld, C. Alberti, A. Lapeyraque, A. Bensman et al., Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil, Pediatric Nephrology, vol.19, issue.1, 2004.
DOI : 10.1007/s00467-003-1300-4

R. Hogg, L. Fitzgibbons, J. Bruick, M. Bunke, B. Ault et al., Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group A prospective study on the use of mycophenolate mofetil in children with cyclosporinedependent nephrotic syndrome, ):1173?8. 77. Fujinaga S, pp.71-77, 2006.

T. Ulinski, L. Dubourg, M. Saïd, B. Parchoux, B. Ranchin et al., Switch from cyclosporine A to mycophenolate mofetil in nephrotic children, Pediatric Nephrology, vol.19, issue.4, pp.482-487, 2005.
DOI : 10.1007/s00467-004-1778-4

S. Mendizábal, I. Zamora, O. Berbel, M. Sanahuja, J. Fuentes et al., Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome, Pediatric Nephrology, vol.12, issue.7, pp.914-923, 2005.
DOI : 10.1007/s00467-005-1877-x

J. Kist-van-holthe, E. Levtchenko, J. Nauta, W. Hop, and A. Van-der-heijden, Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome, J Am Soc Nephrol. oct Pediatr Nephrol. nov, vol.2423, issue.1011, pp.2013-2033, 2008.

K. Afzal, A. Bagga, S. Menon, P. Hari, and S. Jordan, Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome, Pediatric Nephrology, vol.2, issue.Suppl 17, pp.2059-65, 2007.
DOI : 10.1007/s00467-007-0617-9

S. Banerjee, A. Pahari, J. Sengupta, S. Patnaik, N. Larkins et al., Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children, ):93?7. 84, pp.271-82, 2001.

E. Hodson, N. Willis, and J. Craig, Non-corticosteroid treatment for nephrotic syndrome in children, Cochrane Database Syst Rev, vol.59, issue.2, p.2290, 2008.
DOI : 10.1002/14651858.CD002290.pub3

W. Wang, Y. Xia, J. Mao, Y. Chen, D. Wang et al., Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome, Pediatric Nephrology, vol.15, issue.11, pp.2073-2082, 2012.
DOI : 10.1007/s00467-012-2228-3

S. Kengne-wafo, L. Massella, F. Diomedi-camassei, A. Gianviti, M. Vivarelli et al., Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome, 1409?16. 89. Guigonis V, 2009.

M. Afanetti, Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases Fatal pulmonary fibrosis after rituximab administration Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome, ):1269?79. 90. Chaumais M, pp.1875-1884, 2008.

G. Schwartz, A. Muñoz, M. Schneider, R. Mak, F. Kaskel et al., New Equations to Estimate GFR in Children with CKD, Journal of the American Society of Nephrology, vol.20, issue.3, pp.629-666, 2009.
DOI : 10.1681/ASN.2008030287